Tumor necrosis factor inhibitors and cardiovascular outcomes in adults with moderate-to-severe plaque psoriasis: a systematic review and meta-analysis☆
- 1Department of Epidemiology, Universidad El Bosque, Bogotá, Colombia
- 2School of Medicine, Fundación Universitaria de Ciencias de la Salud, Bogotá, Colombia
- 3Department of Epidemiology, Universidad de Boyacá, Tunja, Colombia
Abstract
Background: Moderate-to-severe plaque psoriasis is associated with persistent systemic inflammation and increased cardiovascular risk.
Objectives: To evaluate the association between anti-TNF therapy and clinical cardiovascular outcomes in adults with moderate-to-severe plaque psoriasis.
Methods: The authors conducted a systematic review and meta-analysis in accordance with PRISMA 2020 and prospectively registered the protocol in PROSPERO (CRD420251270784). Randomized controlled trials and comparative observational studies evaluating anti-TNF therapy versus placebo, no anti-TNF exposure, topical therapy and/or phototherapy, or non-biologic systemic therapy were eligible. Outcomes of interest were Major Adverse Cardiovascular Events (MACE), myocardial infarction, stroke, cardiovascular death, heart failure, atrial fibrillation, venous thromboembolism, and all-cause mortality.
Results: Fourteen studies were included. In randomized evidence, anti-TNF therapy was not associated with significant differences in the risk of MACE, myocardial infarction, stroke, or heart failure. In observational analyses stratified by comparator, anti-TNF therapy was associated with a lower pooled risk of reported cardiovascular events versus topical therapy, but not versus oral therapy or phototherapy.
Study limitations: The available evidence was limited by short follow-up in randomized trials, low cardiovascular event counts, wide confidence intervals, and indirect assessment of cardiovascular outcomes, as most trials were designed primarily for dermatologic efficacy and general safety rather than cardiovascular endpoints.
Conclusions: Anti-TNF agents were not associated with a clear increase in major cardiovascular risk and appear to have an acceptable short-term cardiovascular safety profile. However, current evidence does not establish a conclusive cardioprotective effect, and larger prospective studies with longer follow-up are needed.
Related
- Adjusted Comparative Treatment Persistence of IL-23p19 Versus IL-17 Pathway Inhibitors in Adults With Plaque Psoriasis: A Systematic Review and Exploratory Meta-analysis of Real-World Time-to-Discontinuation Estimates
- Cardiovascular and mortality outcomes with JAK versus TNF inhibitors in rheumatoid arthritis: a target trial emulation (CARDINAL-RA)
- JAK1 Inhibitors for Eczematous Eruptions Following Anti-IL-17A Therapy in Psoriasis: A Case Series
- Association between antibiotic exposure and survival outcomes in hepatocellular carcinoma patients treated with immune checkpoint inhibitors: a systematic review and meta-analysis
- Less Is More: Cost-Effective Psoriasis Management via Disease-Driven Dosing of IL-17/IL-23 Inhibitors.
BibTeX
@article{rodriguez2026tumor,
title = {{Tumor necrosis factor inhibitors and cardiovascular outcomes in adults with moderate-to-severe plaque psoriasis: a systematic review and meta-analysis☆}},
author = {Luisa Fernanda Mesa Rodríguez and Alejandro Zambrano Aristizábal and Juan David Vega Padilla},
journal = {Anais Brasileiros de Dermatologia},
year = {2026},
month = oct,
doi = {10.1016/j.abd.2026.501473},
url = {https://doi.org/10.1016/j.abd.2026.501473},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Tumor necrosis factor inhibitors and cardiovascular outcomes in adults with moderate-to-severe plaque psoriasis: a systematic review and meta-analysis☆
AU - Luisa Fernanda Mesa Rodríguez
AU - Alejandro Zambrano Aristizábal
AU - Juan David Vega Padilla
PY - 2026
DA - 2026/10/27
JO - Anais Brasileiros de Dermatologia
DO - 10.1016/j.abd.2026.501473
UR - https://doi.org/10.1016/j.abd.2026.501473
AB - Background: Moderate-to-severe plaque psoriasis is associated with persistent systemic inflammation and increased cardiovascular risk. Objectives: To evaluate the association between anti-TNF therapy and clinical cardiovascular outcomes in adults with moderate-to-severe plaque psoriasis. Methods: The authors conducted a systematic review and meta-analysis in accordance with PRISMA 2020 and prospectively registered the protocol in PROSPERO (CRD420251270784). Randomized controlled trials and comparative observational studies evaluating anti-TNF therapy versus placebo, no anti-TNF exposure, topical therapy and/or phototherapy, or non-biologic systemic therapy were eligible. Outcomes of interest were Major Adverse Cardiovascular Events (MACE), myocardial infarction, stroke, cardiovascular death, heart failure, atrial fibrillation, venous thromboembolism, and all-cause mortality. Results: Fourteen studies were included. In randomized evidence, anti-TNF therapy was not associated with significant differences in the risk of MACE, myocardial infarction, stroke, or heart failure. In observational analyses stratified by comparator, anti-TNF therapy was associated with a lower pooled risk of reported cardiovascular events versus topical therapy, but not versus oral therapy or phototherapy. Study limitations: The available evidence was limited by short follow-up in randomized trials, low cardiovascular event counts, wide confidence intervals, and indirect assessment of cardiovascular outcomes, as most trials were designed primarily for dermatologic efficacy and general safety rather than cardiovascular endpoints. Conclusions: Anti-TNF agents were not associated with a clear increase in major cardiovascular risk and appear to have an acceptable short-term cardiovascular safety profile. However, current evidence does not establish a conclusive cardioprotective effect, and larger prospective studies with longer follow-up are needed.
SN - 0365-0596
SN - 1806-4841
ER -